ES2158943T3 - Peptidos derivados del precursor del antigeno de rechazo tumoral mage-2 aislados, y usos de los mismos. - Google Patents
Peptidos derivados del precursor del antigeno de rechazo tumoral mage-2 aislados, y usos de los mismos.Info
- Publication number
- ES2158943T3 ES2158943T3 ES95914792T ES95914792T ES2158943T3 ES 2158943 T3 ES2158943 T3 ES 2158943T3 ES 95914792 T ES95914792 T ES 95914792T ES 95914792 T ES95914792 T ES 95914792T ES 2158943 T3 ES2158943 T3 ES 2158943T3
- Authority
- ES
- Spain
- Prior art keywords
- precursor
- peptides derived
- same
- tumor rejection
- rejection antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002243 precursor Substances 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/828—Cancer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
LA INVENCION DESCRIBE PEPTIDOS DERIVADOS DEL PRECURSOR MAGE NEN A LAS MOLECULAS HLA AN LA PRODUCCION DE CELULAS T CITOLITICAS. LOS "CTLS" RESULTANTES SON ESPECIFICOS PARA COMPLEJOS DE HLA OS COMPLEJOS PUEDEN UTILIZARSE PARA GENERAR ANTICUERPOS MONOCLONALES. LAS CELULAS T CITOLITICAS PRODUCIDAS PUEDEN UTILIZARSE EN EL CONTEXTO DE LA INMUNOTERAPIA, COMO EN UNA TRANSFERENCIA ADOPTIVA.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/217,188 US5554724A (en) | 1994-03-24 | 1994-03-24 | Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2158943T3 true ES2158943T3 (es) | 2001-09-16 |
Family
ID=22810016
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES95914792T Expired - Lifetime ES2158943T3 (es) | 1994-03-24 | 1995-03-21 | Peptidos derivados del precursor del antigeno de rechazo tumoral mage-2 aislados, y usos de los mismos. |
Country Status (17)
Country | Link |
---|---|
US (3) | US5554724A (es) |
EP (1) | EP0810870B1 (es) |
JP (1) | JP3360137B2 (es) |
CN (1) | CN1149257A (es) |
AT (1) | ATE201214T1 (es) |
AU (1) | AU682597B2 (es) |
CA (1) | CA2186006A1 (es) |
DE (1) | DE69520959T2 (es) |
DK (1) | DK0810870T3 (es) |
ES (1) | ES2158943T3 (es) |
FI (1) | FI963780A (es) |
GR (1) | GR3036320T3 (es) |
NO (1) | NO963918L (es) |
NZ (2) | NZ283561A (es) |
PT (1) | PT810870E (es) |
WO (1) | WO1995025530A1 (es) |
ZA (1) | ZA952375B (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7252829B1 (en) * | 1998-06-17 | 2007-08-07 | Idm Pharma, Inc. | HLA binding peptides and their uses |
IL105554A (en) * | 1992-05-05 | 1999-08-17 | Univ Leiden | Peptides of human papillomavirus for use in preparations elicit a human T cell response |
US5686068A (en) * | 1994-03-24 | 1997-11-11 | Ludwig Institute For Cancer Research | Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof |
US5554724A (en) * | 1994-03-24 | 1996-09-10 | University Of Leiden | Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof |
US5830753A (en) * | 1994-09-30 | 1998-11-03 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof. |
US5587289A (en) * | 1995-03-14 | 1996-12-24 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof |
US5821122A (en) * | 1995-06-07 | 1998-10-13 | Inserm (Institute Nat'l De La Sante Et De La Recherche . .) | Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof |
AU740222C (en) * | 1996-03-20 | 2002-10-10 | Genzyme Corporation | A method for identifying cytotoxic T-cell epitopes |
US6087441A (en) * | 1997-02-05 | 2000-07-11 | Ludwig Institute For Cancer Research | Structurally modified peptides that are resistant to peptidase degradation |
US6027924A (en) * | 1997-04-25 | 2000-02-22 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecule coding for tumor rejection antigen precursor MAGE-C1 and uses thereof |
US6680191B1 (en) | 1997-04-25 | 2004-01-20 | Ludwig Institute For Cancer | Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B FAMILIES and uses thereof |
US6025470A (en) * | 1997-06-23 | 2000-02-15 | Ludwig Institute For Cancer Research | Isolated nona- and decapeptides which bind to HLA molecules, and the use thereof |
AU732468B2 (en) * | 1997-06-23 | 2001-04-26 | Ludwig Institute For Cancer Research | Isolated nona- and decapeptides which bind to HLA molecules, and the use thereof |
EP1103561B1 (en) * | 1998-07-28 | 2006-04-19 | Green Peptide Co., Ltd. | Hla-a2 restraint tumor antigen peptide originating in sart-1 |
GB9826143D0 (en) * | 1998-11-27 | 1999-01-20 | Ludwig Inst Cancer Res | Tumour rejection antigens |
DE60038971D1 (de) | 1999-10-22 | 2008-07-03 | Aventis Pasteur | Verfahren zur erregung und/oder verstärkung der immunantwort gegen tumorantigene |
EP1282702B1 (en) * | 2000-05-10 | 2006-11-29 | Sanofi Pasteur Limited | Immunogenic polypeptides encoded by mage minigenes and uses thereof |
DK1453471T3 (da) * | 2001-11-07 | 2011-03-28 | Mannkind Corp | Ekspressionsvektorer, der koder for epitoper af antigener, og fremgangsmåde til deres konstruktion |
EP1864691B1 (en) | 2002-04-09 | 2011-07-20 | Sanofi Pasteur Limited | Modified CEA nucleic acid and expression vectors |
AU2003258134A1 (en) * | 2002-08-09 | 2004-02-25 | Applera Corporation | Lung cancer target proteins and use thereof |
EP1556082A1 (en) * | 2002-10-22 | 2005-07-27 | Aventis Pasteur Limited | Anti-cancer vaccines and high-dose cytokines as adjuvants |
US20080274129A1 (en) | 2003-04-18 | 2008-11-06 | Fikes John D | Hla-A2 Tumor Associated Antigen Peptides and Compositions |
CA2550583C (en) * | 2003-10-08 | 2013-01-15 | Sanofi Pasteur, Inc. | Modified cea /b7 vector |
US7338670B2 (en) | 2005-04-14 | 2008-03-04 | Duke University | Use of an agent that restores tissue perfusion and oxygenation |
JP5792630B2 (ja) | 2009-01-28 | 2015-10-14 | エピミューン,インコーポレイティド | Pan−dr結合ポリペプチドおよびその使用 |
CN103403026B (zh) | 2009-09-25 | 2016-05-11 | 美国政府(由卫生和人类服务部的部长所代表) | Hiv-1中和抗体及其用途 |
KR20140016315A (ko) | 2011-03-07 | 2014-02-07 | 크리에이티브 네일 디자인 인코포레이티드 | Uv-경화성 미용 손톱 코팅제를 위한 조성물 및 방법 |
WO2013137953A1 (en) | 2012-03-15 | 2013-09-19 | Exxonmobil Chemical Patents Inc. | Oxygen tailoring of polyethylene |
FR3008099B1 (fr) | 2013-07-05 | 2020-08-07 | Commissariat Energie Atomique | Peptides immunogenes de l'antigene tumoral cycline b1 |
FR3090319A1 (fr) | 2018-12-21 | 2020-06-26 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Melanges d’epitopes t cd8+ immunogenes de la cycline b1 |
CN116731155B (zh) * | 2022-09-21 | 2024-03-22 | 新景智源生物科技(苏州)有限公司 | 人乳头瘤病毒特异性t细胞受体、表达其的细胞和其用途 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5342774A (en) * | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
ATE342730T1 (de) * | 1992-08-07 | 2006-11-15 | Pharmexa Inc | Hla bindepeptide und ihre verwendungen |
US5462871A (en) * | 1992-08-31 | 1995-10-31 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules which encode MAGE derived nonapeptides |
US5405940A (en) * | 1992-08-31 | 1995-04-11 | Ludwig Institute For Cancer Research | Isolated nonapeptides derived from MAGE genes and uses thereof |
US5487974A (en) * | 1992-12-22 | 1996-01-30 | Ludwig Institute For Cancer-Research | Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells |
AU6359494A (en) * | 1993-03-05 | 1994-09-26 | Epimmune, Inc. | Hla-a2.1 binding peptides and their uses |
US5554506A (en) * | 1994-03-24 | 1996-09-10 | Ludwig Institute For Cancer Research | Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof |
US5686068A (en) * | 1994-03-24 | 1997-11-11 | Ludwig Institute For Cancer Research | Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof |
US5554724A (en) * | 1994-03-24 | 1996-09-10 | University Of Leiden | Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof |
-
1994
- 1994-03-24 US US08/217,188 patent/US5554724A/en not_active Expired - Lifetime
-
1995
- 1995-03-21 EP EP95914792A patent/EP0810870B1/en not_active Expired - Lifetime
- 1995-03-21 DK DK95914792T patent/DK0810870T3/da active
- 1995-03-21 NZ NZ283561A patent/NZ283561A/en not_active IP Right Cessation
- 1995-03-21 WO PCT/US1995/003535 patent/WO1995025530A1/en active IP Right Grant
- 1995-03-21 AU AU21893/95A patent/AU682597B2/en not_active Expired
- 1995-03-21 CN CN95192262A patent/CN1149257A/zh active Pending
- 1995-03-21 PT PT95914792T patent/PT810870E/pt unknown
- 1995-03-21 ES ES95914792T patent/ES2158943T3/es not_active Expired - Lifetime
- 1995-03-21 AT AT95914792T patent/ATE201214T1/de active
- 1995-03-21 NZ NZ329695A patent/NZ329695A/xx unknown
- 1995-03-21 DE DE69520959T patent/DE69520959T2/de not_active Expired - Lifetime
- 1995-03-21 CA CA002186006A patent/CA2186006A1/en not_active Abandoned
- 1995-03-21 JP JP52477995A patent/JP3360137B2/ja not_active Expired - Lifetime
- 1995-03-23 ZA ZA952375A patent/ZA952375B/xx unknown
-
1996
- 1996-06-21 US US08/667,725 patent/US6063900A/en not_active Expired - Lifetime
- 1996-09-19 NO NO963918A patent/NO963918L/no not_active Application Discontinuation
- 1996-09-23 FI FI963780A patent/FI963780A/fi unknown
-
1998
- 1998-01-15 US US09/007,748 patent/US6147187A/en not_active Expired - Lifetime
-
2001
- 2001-08-03 GR GR20010401171T patent/GR3036320T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
ZA952375B (en) | 1995-12-15 |
NZ329695A (en) | 2000-05-26 |
GR3036320T3 (en) | 2001-11-30 |
ATE201214T1 (de) | 2001-06-15 |
PT810870E (pt) | 2001-09-28 |
DK0810870T3 (da) | 2001-07-23 |
AU2189395A (en) | 1995-10-09 |
JP3360137B2 (ja) | 2002-12-24 |
US6147187A (en) | 2000-11-14 |
CA2186006A1 (en) | 1995-09-28 |
JPH10502329A (ja) | 1998-03-03 |
FI963780A0 (fi) | 1996-09-23 |
DE69520959D1 (de) | 2001-06-21 |
FI963780A (fi) | 1996-09-23 |
NO963918L (no) | 1996-11-20 |
US6063900A (en) | 2000-05-16 |
NO963918D0 (no) | 1996-09-19 |
DE69520959T2 (de) | 2002-03-28 |
EP0810870A1 (en) | 1997-12-10 |
US5554724A (en) | 1996-09-10 |
WO1995025530A1 (en) | 1995-09-28 |
EP0810870B1 (en) | 2001-05-16 |
EP0810870A4 (en) | 1998-11-25 |
AU682597B2 (en) | 1997-10-09 |
CN1149257A (zh) | 1997-05-07 |
NZ283561A (en) | 1998-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2158943T3 (es) | Peptidos derivados del precursor del antigeno de rechazo tumoral mage-2 aislados, y usos de los mismos. | |
ES2174931T3 (es) | Anticuerpos monoclonales que se unen al precursor del antigeno de rechazo de tumores mage-1, mage-1 recombinante y peptidos inmunogenos derivados de mage-1. | |
ES2134294T3 (es) | Reactividad inmune para oncogenes expresados activos para la diagnosis y el tratamiento de tumores malignos. | |
RU2009130954A (ru) | Применение белков теплового шока для улучшения терапевтического эффекта невакционного лечебного воздействия | |
ES2135051T3 (es) | Peptidos derivados de mage-3, aislados, que forman complejos con moleculas hla-a2 y usos de los mismos. | |
PE20220142A1 (es) | Anticuerpos de cadena pesada que se unen al psma | |
Jäger et al. | Cytolytic T cell reactivity against melanoma-associated differentiation antigens in peripheral blood of melanoma patients and healthy individuals | |
AR038700A1 (es) | Anticuerpos monoclonales anti-tenascina humana | |
EA200702202A1 (ru) | Идентификация представленных hla-a2 т-клеточных эпитопов, полученных из раково-эмбрионального антиген-незрелого рецепторного белка ламинила, и их применение | |
JP2020534313A5 (es) | ||
ES2123558T3 (es) | Antigenos peptidicos del vhc y procedimiento para la determinacion del vhc. | |
CY1123520T1 (el) | Μεθοδοι για την προβλεψη της χρησιμοτητας των νεων αντιγονων για ανοσοθεραπεια | |
CY1110235T1 (el) | Χρηση αλλογενετικων κυτταρικων γραμμων για τη φορτωση κυτταρων που εμφανιζουν αντιγονο για την προκληση ή εξαλειψη ανοσολογικων απαντησεων | |
ES2126145T3 (es) | Redireccionamiento de anticuerpos. | |
HUP0204216A2 (en) | A new use of antibodies as vaccines | |
Brimnes et al. | Generation of autologous tumor-specific T cells for adoptive transfer based on vaccination, in vitro restimulation and CD3/CD28 dynabead-induced T cell expansion | |
Benlalam et al. | Infusion of Melan-A/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients | |
UY26266A1 (es) | Antigeno asociado con tumores (r11) ley 17164 | |
ES2143996T3 (es) | Antigenos peptidicos del hcv y procedimiento para la determinacion del hcv. | |
Lewis et al. | Definition of tumor antigens suitable for vaccine construction | |
ES2168514T3 (es) | Antigenos de rechazo tumoral presentados por moleculas de hla b44 y usos de los mismos. | |
Mohamed et al. | Long-lived fusions of human haematological tumour cells and B-lymphoblastoid cells induce tumour antigen-specific cytotoxic T-cell responses in vitro | |
Lotz et al. | Targeting positive regulatory domain I-binding factor 1 and X box-binding protein 1 transcription factors by multiple myeloma-reactive CTL | |
UY26170A1 (es) | Antigeno (c42) asociados a tumores | |
Embleton et al. | Demonstration and partial purification of common melanoma-associated antigen (s) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 810870 Country of ref document: ES |